This episode of the Nucleate Podcast features host Sam Kessler in conversation with Nolan Townsend, CEO of Lexeo Therapeutics, a New York-based clinical-stage biotech developing gene therapies for genetically driven cardiovascular disease. Nolan traces his path from healthcare investment banking at Lehman Brothers into more than a decade at Pfizer, where international P&L roles in Korea, Ukraine, and Western Europe sharpened his ability to navigate ambiguity and different healthcare systems, and where leading Pfizer's rare disease unit gave him a front-row seat as tafamidis, a treatment for a once-obscure cardiac amyloidosis, grew into one of the company's largest products. That experience drove his decision to found Lexeo in January 2020, just months before COVID hit, betting that cardiovascular disease would follow oncology's path toward genetically defined subtypes treatable with precision therapies delivered via AAV-vector gene therapy. The conversation then breaks down Lexeo's pipeline and the mechanics of building a biotech company. Nolan describes lead programs in Friedreich's ataxia-associated cardiomyopathy and arrhythmogenic cardiomyopathy, explains why the company narrowed its focus away from a CNS/Alzheimer's program despite promising APOE-gene-therapy science, and offers candid advice on fundraising in a cooled IPO market, including the importance of de-risking a story, avoiding pure me-too positioning, and recruiting strong advisors to unlock larger tranche financings. He closes with reflections on mentors like Ron Crystal and Steve Altschuler, Clayton Christensen's disruptive innovation theory as a guiding framework, and lastly takes on the most underrated CEO skill (managing unpredictability) and what he'd do outside biotech (play tennis).
Here is a segment breakdown of the episode:
0:00–1:42 — Intro and guest background: host frames the episode and introduces Nolan Townsend's career across Wall Street, Pfizer, and Lexeo.
1:42–3:21 — From finance to healthcare: what drew Nolan into life sciences and the appeal of the industry's complexity.
3:21–10:13 — Pfizer's international roles: P&L leadership in Korea, Ukraine, and beyond, and how working across health systems and cultures shaped him.
10:14–19:00 — Rare disease leadership at Pfizer: the tafamidis/TTR amyloid cardiomyopathy story and its influence on Lexeo's founding thesis.
19:00–24:16 — Founding Lexeo in January 2020: the decision to leave Pfizer, launching amid COVID, and building a team remotely.
24:19–37:39 — Lexeo's scientific thesis: applying oncology's precision-medicine model to cardiac disease, the lead pipeline (Friedreich's ataxia, arrhythmogenic cardiomyopathy), and the Alzheimer's/APOE program and why it was deprioritized.
37:39–47:20 — Fundraising strategy: de-risking the story, the cooled IPO market, tranche financing, and advice for founders raising seed/Series A rounds.
47:20–50:00 — Mentors: Ron Crystal, Steve Altschuler, Ted Love, and the lessons drawn from each.
50:23–56:04 — Rapid-fire questions: influential book (Clayton Christensen), views on what's holding back broader use of gene therapy, and the most underrated CEO skill.
56:04–57:33 — Closing question (life outside biotech) and sign-off.